Disruptive Tech Research
  • About
  • Media
  • Research
  • Subscribe
  • Log in
Select Page

[Video] Cue Biopharma Q&A Session With Dr. D.J. Verret

by Lou Basenese | Feb 21, 2022 | CUE

In this 1.5 hour webinar, Dr. D.J. Verret shares his unique clinical perspective on Cue Biopharma’s (CUE) approach and latest data

[CUE] “That Data Is Amazing!” So Why Is The Stock Down?

[CUE] “That Data Is Amazing!” So Why Is The Stock Down?

by Lou Basenese | Jan 27, 2022 | CUE

Here’s a full rundown on the important takeaways from CUE’s conference call and my thoughts on the recent trading activity…

[Video] What To Expect From CUE This Afternoon

[Video] What To Expect From CUE This Afternoon

by Lou Basenese | Jan 26, 2022 | CUE

Like expectant parents, everyone’s wondering what will be revealed on today’s update call. Here are my reasonable expectations…

CUE: New Data (And Stock Highs) Coming?

CUE: New Data (And Stock Highs) Coming?

by Lou Basenese | Sep 22, 2021 | CUE

Every time Cue Biopharma (CUE) attends a conference, management shares new platform-validating data. Here’s what to expect today…

CUE: Last Call To Back Up The Truck

CUE: Last Call To Back Up The Truck

by Lou Basenese | May 10, 2021 | CUE

Cue Biopharma (CUE) released a major, platform validating data this morning. Here are the 5 key takeaways…

[Video] Urgent Update On ATOM, Plus Two More Strong Buys

by Lou Basenese | Apr 30, 2021 | ATOM, CUE, LTRN

Ignore the short-term price action in Atomera (ATOM) and focus on the steadily improving business fundamentals…

« Older Entries

Your account

Sign in

Research Links

  • Real-Time Blog
  • Active Recs
  • Archive

Recent Posts

  • Q2 2022 Portfolio Review & Outlook
  • ATOM: Lands Another “Major” Foundry Customer, Plus 10 Takeaways From Q1 Report
  • [IMNM] Biotech Absurdity
  • [Video] Cue Biopharma Q&A Session With Dr. D.J. Verret
  • [Video] ATOM: 5 Key Takeaways From The Q4 2021 Report
  • RESN: Time To Lock In Our 5G Gains
  • [CUE] “That Data Is Amazing!” So Why Is The Stock Down?